Literature DB >> 16516275

Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada.

Susan R Kahn1, Akbar Panju, William Geerts, Graham F Pineo, Louis Desjardins, Alexander G G Turpie, Stanislav Glezer, Lehana Thabane, Rolf J Sebaldt.   

Abstract

BACKGROUND: Venous thromboembolism (VTE) prophylaxis in acutely ill medical patients has been shown to be safe and effective. Underutilization of this patient safety practice may result in avoidable mortality and morbidity.
OBJECTIVES: We aimed to determine the proportion of hospitalized, acutely ill medical patients across Canada who were eligible to receive thromboprophylaxis and to evaluate the frequency, determinants and appropriateness of its use. PATIENTS/
METHODS: CURVE is a national, multicenter chart audit of 29 Canadian hospitals. Data were collected on consecutive patients admitted to hospital for an acute medical illness during a defined 3-week study period. Information on demographic and clinical characteristics, risk factors for VTE and bleeding and use of VTE prophylaxis were recorded. The indications for and appropriateness of VTE prophylaxis were assessed using pre-specified criteria based on international consensus guidelines. Multivariable analyses were performed to identify determinants of prophylaxis use.
RESULTS: Of the 4124 medical admissions screened over the study period, 1894 patients (46%) were eligible for study inclusion. The most common specified admitting diagnoses were severe infection (28%), COPD exacerbation or respiratory failure (12%), malignancy (9%) and congestive heart failure (8%). Thromboprophylaxis was indicated in 1702 (90%) study patients. Overall, some form of prophylaxis was administered to 23% of all patients. However, only 16% received appropriate thromboprophylaxis. Factors independently associated with greater use of prophylaxis included internist (vs. other specialty) as attending physician (OR 1.33, 95% confidence interval (CI) [1.03, 1.71]), university-associated (vs. community) hospital (OR 1.46, 95% CI [1.03, 2.07]), immobilization (per day) (OR 1.60, 95% CI [1.45, 1.77]), presence of >or=1 VTE risk factors (OR=1.78, 95% CI [1.35, 2.34]) and duration of hospitalization (per day of stay) (OR 1.05, 95% CI [1.03, 1.07]), however, use of prophylaxis was unacceptably low in all groups. Patients with cancer had a significantly reduced likelihood of receiving prophylaxis (OR=0.40, 95% CI [0.24, 0.68]). Presence of risk factors for bleeding did not influence the use or choice of prophylaxis.
CONCLUSION: Most patients hospitalized for medical illness had indications for thromboprophylaxis, yet only 16% received appropriate prophylaxis. Efforts should be made to elucidate the reasons that underlie the very low rate of thromboprophylaxis in medical patients and to develop and test strategies to improve implementation of this patient safety practice.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16516275     DOI: 10.1016/j.thromres.2006.01.011

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  64 in total

Review 1.  Cancer, clots and consensus: new understanding of an old problem.

Authors:  Gary H Lyman; Alok A Khorana
Journal:  J Clin Oncol       Date:  2009-09-14       Impact factor: 44.544

Review 2.  Rationale supporting an "opt-out" policy for pharmacological venous thromboembolism prophylaxis in hospitalized medical patients.

Authors:  Samuel Z Goldhaber
Journal:  J Thromb Thrombolysis       Date:  2013-04       Impact factor: 2.300

3.  Frequency of thromboprophylaxis and incidence of in-hospital venous thromboembolism in a cohort of emergency department patients.

Authors:  Alan E Jones; Zachary Fordham; Vasilios Yiannibas; Charles L Johnson; Jeffrey A Kline
Journal:  J Thromb Thrombolysis       Date:  2007-06-19       Impact factor: 2.300

4.  Adherence to thromboprophylaxis guidelines in elderly patients with hospital acquired venous thromboembolism: a case control study.

Authors:  Jason Suh; Amishi Desai; Anish Desai; Josephine Dela Cruz; Anusiyanthan Mariampillai; Alexander Hindenburg
Journal:  J Thromb Thrombolysis       Date:  2017-02       Impact factor: 2.300

5.  Computerized decision support for the cardiovascular clinician: applications for venous thromboembolism prevention and beyond.

Authors:  Gregory Piazza; Samuel Z Goldhaber
Journal:  Circulation       Date:  2009-09-22       Impact factor: 29.690

Review 6.  Impact on patient care: patient case through the continuum of care.

Authors:  Scott Kaatz
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

7.  Assessment of risk and prophylaxis for deep vein thrombosis and pulmonary embolism in medically ill patients during their early days of hospital stay at a tertiary care center in a developing country.

Authors:  Ambarish Pandey; Nivedita Patni; Mansher Singh; Randeep Guleria
Journal:  Vasc Health Risk Manag       Date:  2009-08-06

Review 8.  The potential benefits of low-molecular-weight heparins in cancer patients.

Authors:  Francisco Robert
Journal:  J Hematol Oncol       Date:  2010-01-14       Impact factor: 17.388

9.  Designing and implementing effective venous thromboembolism prevention protocols: lessons from collaborative efforts.

Authors:  Greg Maynard; Jason Stein
Journal:  J Thromb Thrombolysis       Date:  2010-02       Impact factor: 2.300

10.  Are hospitals delivering appropriate VTE prevention? The venous thromboembolism study to assess the rate of thromboprophylaxis (VTE start).

Authors:  A Amin; A C Spyropoulos; P Dobesh; A Shorr; M Hussein; E Mozaffari; J S Benner
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.